Weight loss drugs may protect against heart failure
Medical Xpress reports a Cedars-Sinai laboratory study, published in the European Heart Journal, in which low-dose semaglutide was given to rats and minipigs modelling obesity-associated heart failure with preserved ejection fraction. The drug did not reduce body weight but reduced heart stiffness, enlargement and scarring, and cleared fat around the heart and liver. Findings are in animals; researchers say they support studying GLP-1 drugs for heart failure.
Why it matters: Relevant to clinicians who manage heart failure or medical weight loss, and to readers following early research on GLP-1 drugs and heart health.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to medicalxpress.com. October 14, 2026.
